EGFR and neoplasm: These observations are consistent with previous reports of reduced tumour vascular permeability/perfusion after Vandetanib treatment, a VEGFR and EGFR inhibitor (Checkley et al, 2003).The results from the study with Vandetanib showing that the schedule of concomitant association of Vandetanib results in poor enhancement of radiation were attributed to decreased perfusion in the concurrent schedule such that radiotherapy was impaired (Williams et al, 2004).